GENE ONLINE|News &
Market Insight on FDA-approvals: Rise of First-in-class and Regenerative Innovations
Achieving market entry for new drugs has never been more challenging, especially for non-COVID medications during a time shrouded in COVID-19. Notably, the US FDA has pushed to accelerate the launches of non-COVID medications and has been reviewing more next-generation (Next-Gen) drugs in the last 14 months. Next-Gen drugs, here chiefly describing the first-in-class and regeneration ones which encompass strong clinical benefits and market competitions, are evolving fast year on year.
GO Prime with only $1.49 now
LATEST
American Heart Association Reports 400 Milligrams of Daily Caffeine Is Safe for Most Adults
2026-07-20
Translational Frontiers in Regenerative Medicine: Navigating Clinical Bottlenecks and Commercial Scale for Advanced Cell Therapies
2026-07-20
National Bank of Georgia Partners with Nasdaq Calypso to Modernize Treasury Infrastructure for Five Major Banks
2026-07-20
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
